ARIX — Arix Bioscience Income Statement
0.000.00%
Last trade - 00:00- £183.80m
- £82.85m
- £0.11m
- 29
- 34
- 90
- 48
Annual income statement for Arix Bioscience, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.33 | 0.506 | 0.477 | 0.34 | 0.112 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 11.7 | 11 | 7.93 | 12.5 | 5.41 |
| Operating Profit | -10.4 | -10.5 | -7.45 | -12.2 | -5.29 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 42.8 | -75.6 | 126 | -61.1 | -27.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 36.9 | -69.7 | 126 | -61.1 | -27.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 36.9 | -69.7 | 126 | -61.1 | -27.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | 36.9 | -69.7 | 126 | -61.1 | -27.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.287 | -0.53 | 0.888 | -0.423 | -0.222 |